Navigation Links
FDA Approves New Skin Cancer Drug First Tested in Arizona by Scottsdale Healthcare and TGen
Date:2/1/2012

SCOTTSDALE, Ariz., Feb. 1, 2012 /PRNewswire-USNewswire/ -- A new skin cancer drug tested for the first time in the world five years ago at the Virginia G. Piper Cancer Center at Scottsdale Healthcare just received expedited approval by the U.S. Food and Drug Administration, a remarkable accomplishment in new drug development.

(Photo: http://photos.prnewswire.com/prnh/20120201/DC45876)

Vismodegib (GDC-0449) was administered for the first time in the world Jan. 23, 2007 in a phase I clinical trial at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership with the Translational Genomics Research Institute (TGen). Vismodegib received FDA approval on Jan. 30, 2012. Clinical trials progress through three phases and can take up to 10 years or more to successfully complete.

The drug is the first to receive FDA approval to treat inoperable basal cell carcinoma. Successful early trial results led to a broader subsequent study sponsored by Genentech. Continued positive study results led to Monday's FDA approval for marketing the drug under the name Erivedge.

Vismodegib is used to treat adult patients with advanced basal cell carcinoma, the most common type of skin cancer. It is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body (metastatic), according to the FDA.

Arizona has one of the highest incidences of skin cancer in the world, and in the United States two million new cases of basal cell carcinoma are diagnosed every year. Most instances of basal cell cancer can be effectively treated, but in some cases, the cancer cells spread and develop an aggressive form of the cancer that does not respond to standard surgical treatment.

"Until now, we did not have any treatments that can effectively slow the t
'/>"/>

SOURCE Scottsdale Healthcare
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)...  Sorrento Therapeutics, Inc. (OTCBB: SRNE; or STI) ... Business Technology Transfer Research (STTR) grant (#1R42AI098182-02) from ... (NIAID), a division of the National Institutes of ... antibody therapeutics to combat Staphylococcus aureus ... methicillin-resistant S. aureus (MRSA), was renewed ...
(Date:5/17/2013)... 17, 2013  Sony Biotechnology Inc. ("Sony") today announced the ... and 130um sorting chip.  Sony will also be exhibiting its ... SH800 Cell Sorter, the EC800 flow cytometer, and new SP6800 ... 2013, which will be held at the San ... California , from May 20 - 22.  ...
(Date:5/17/2013)... 2013  TechAtlas Group has announced the release ... map for the Chronic Kidney Disease (CKD) market. ... with drugs and devices currently on the market ... (Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ) ... - renal denervation , diabetic nephropathy - ...
Breaking Medicine Technology:Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4Sony Delivers New Technology for Science to CYTO 2013 2TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2
... Schering-Plough,Corporation (NYSE: SGP ) today announced ... issued a "not-approvable" letter for sugammadex,sodium injection for ... "We are surprised and disappointed with this action, ... approval by the FDA,Advisory Committee on Anesthetics and ...
... Is the First to Receive FDA, Clearance for Diagnosis of ... ... SUNNYVALE, Calif., July 31 Pathwork Diagnostics, Inc.,a molecular diagnostics company ... (FDA) has cleared its Pathwork(R),Tissue of Origin Test for use in ...
Cached Medicine Technology:U.S. FDA Issues Action Letter for Sugammadex 2FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors 2FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors 3FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors 4
(Date:5/19/2013)... Farming methods have changed many times since man ... ago. Most recently, the Green Revolution has transformed farming ... seeds and by applying chemical fertilizers and pesticides. But ... due to the adverse environmental and health effects of ... interest in organic, sustainable farming practices and techniques. Enter ...
(Date:5/19/2013)... Vegas Hotel Escapes, the premier ... the launch it's all new vacation packages for the ... 5/19/2013. Consumers traveling to Las Vegas will be pleased ... VegasHotelEscapes.com's website. Travelers will be pleased to know that ... , Vegas Hotel Escapes specializes in helping consumers ...
(Date:5/19/2013)... May 19, 2013 Exciting new Skin ... is reintroducing a great practice known through the ages ... known as dry body brushing, has so many benefits ... of Sublime Beauty®. "We love that circulation and lymphatic ... largest organ, the skin, is supported through Skin Brushing." ...
(Date:5/19/2013)... Buenos Aires, Argentina: Yoga classes ( clases de ... Argentina by the Sivananda Yoga Vedanta Center. The ... (Barrio Norte). Classes are 90 minutes and are offered ... in a calm environment, allowing visitors to enjoy the ... food, among others. , The Yoga classes follow the ...
(Date:5/19/2013)... Minor fender benders and serious car accidents are ... the accident to respond appropriately to the situation. ... data from 2010, accidents, including car accidents, are the ... in 2005, automobile accident-related deaths cost over ... million drivers and passengers receive treatment in an emergency ...
Breaking Medicine News(10 mins):Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 2Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 3Health News:Exciting New Skin Brushes at Sublime Beauty® Bring Health and Beauty Benefits; Celebrities and Models Know the Secret 2Health News:Clases de Yoga in Buenos Aires, Argentina (Yoga Classes) Now Offered by Sivananda Yoga Vedanta Center 2Health News:Auto Accident Infographic Issued by d’Oliveira & Associates on Steps to Take After a Car Crash 2
... HealthDay Reporter , MONDAY, Nov. 7 (HealthDay News) - More ... drugs, with 32 percent saying they drink, 19 percent saying they ... study shows. , , An even closer look at the data ... to use drugs or alcohol, with almost 48 percent admitting they ...
... by 2007 annual sales of the cards were at 85,000. America ... in the U.S. over the age of 80 is expected to ... how well they live. The new book, Aging Our Way ... of 30 eldersranging in age from 85 to 102living at home ...
... the Johns Hopkins Center for Injury Research and Policy ... a strategic, comprehensive and coordinated approach to fire prevention. ... the state,s fire service, highlights the diversity of prevention ... dedication, and a sense of community are keys to ...
... (November XX, 2011) The Lymphoma Division of the John ... participation from the Facebook groups "Hope for Lymphoma" and "Our ... on Saturday, November 12 from 8:30am 3:45pm. The ... Mantle Cell Lymphoma (MCL) patients and their caregivers coping with ...
... A grant in excess of $3.5 million has been awarded ... to facilitate the production of new and investigational drugs for ... Central Texas cancer research program receiving the award from the ... to fund innovation and commercialization of cancer research in the ...
... published online Nov. 6 in Nature Medicine , investigators ... the development of osteoarthritis is in great part driven by ... view attributing the condition to a lifetime of wear and ... William Robinson, MD, PhD, the study,s senior author, of the ...
Cached Medicine News:Health News:More Than a Third of Teens Turning to Alcohol, Drugs: Study 2Health News:More Than a Third of Teens Turning to Alcohol, Drugs: Study 3Health News:What can we learn from America's fastest growing and least understood age group? 2Health News:Delaware Fire Service offers important lessons for fire prevention programs nationwide 2Health News:John Theurer Cancer Center to host inaugural Mantle Cell Lymphoma Symposium 2Health News:John Theurer Cancer Center to host inaugural Mantle Cell Lymphoma Symposium 3Health News:Osteoarthritis results from inflammatory processes, not just wear and tear, Stanford study suggests 2Health News:Osteoarthritis results from inflammatory processes, not just wear and tear, Stanford study suggests 3Health News:Osteoarthritis results from inflammatory processes, not just wear and tear, Stanford study suggests 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: